Given its immunomodulating effects and the increasingly important link between EGFR inhibitory therapies and tumor immune microenvironment [83], ARID1A changes may provide clues for optimizing immune checkpoint inhibitor therapy in head and neck cancers (Figure 2b). The gene discussed is EGFR; the disease is head and neck cancer.